Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q1 2024 (← Previous) (Next →)

Filing Date: May 15, 2024

Total Value: $1.525B (100.0% shares, 0.0% debt)

Holdings (7)

MRNA Moderna Inc 67.6%

Value $1.03B Shares 9,666,038 Est. Cost $16.43 Unrealized +513.4%

SANA Sana Biotechnology Inc 16.4%

Value $250M Shares 25,001,856 Est. Cost $32.56 Unrealized -77.0%

— Omega Therapeutics Inc 7.0%

Value $107M Shares 29,225,579 Est. Cost $17.39 Unrealized —

FHTX Foghorn Therapeutics Inc 5.6%

Value $85.04M Shares 12,674,120 Est. Cost $19.16 Unrealized -71.0%

DNLI Denali Therapeutics Inc 1.8%

Value $28M Shares 1,364,516 Est. Cost $17.97 Unrealized +4.6%

— Seres Therapeutics Inc 1.2%

Value $17.89M Shares 23,117,045 Est. Cost $7.75 Unrealized —

SYRS Syros Pharmaceuticals Inc 0.5%

Value $6.922M Shares 1,293,849 Est. Cost $7.03 Unrealized -1.7%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	9,666,038	$1.03B	67.6%	$16.43	+513.4%	COM	60770K107
SANA	Sana Biotechnology Inc	25,001,856	$250M	16.4%	$32.56	-77.0%	COM	799566104
—	Omega Therapeutics Inc	29,225,579	$107M	7.0%	$17.39	—	COM	68217N105
FHTX	Foghorn Therapeutics Inc	12,674,120	$85.04M	5.6%	$19.16	-71.0%	COM	344174107
DNLI	Denali Therapeutics Inc	1,364,516	$28M	1.8%	$17.97	+4.6%	COM	24823R105
—	Seres Therapeutics Inc	23,117,045	$17.89M	1.2%	$7.75	—	COM	81750R102
SYRS	Syros Pharmaceuticals Inc	1,293,849	$6.922M	0.5%	$7.03	-1.7%	COM	87184Q206